3[5]Rodriguez TE, Stiff PJ. Current treatment results of allogeneic bone marrow transplantation for acute myeloid and lymphoid leukemia[J]. Curr Hematol Rep, 2003,2(4):295-301.
4[6]Baynes RD, Hamm C, Dansey R, et al. Bone marrow and peripheral blood hematopoietic stem cell transplantation: focus on autografting[J]. Clin Chem, 2000,46(8):1239-51.
5[7]Garcia-Manero G, Faderl S, O'Brien S,et al.Chronic myelogenous leukemia: a review and update of therapeutic strategies[J]. Cancer, 2003,98(3):437-457.
6[8]Mori T, Okamoto S, Matsuoka S, et al. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation[J]. Bone Marrow Transplant, 2000, 25(7):765-769.
7[9]Ljungman P, Brand R, Einsele H, et al. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis[J]. Blood, 2003, 102(13):4255-4260.
8Gratwohl A, Baldomero H, Schwendener A, et al. Predictability of hematopoietie stem cell transplantation rates. Haematologica, 2007 ; 92(12) : 1679 - 1686.
9Anderlini P. Donors, donors, and more donors. Blood, 2009; 114 (18) : 3721 -3722.
10Appelbaum FR. Choosing the source of stem cells for allogenic transplantation: no longer a peripheral issue. Blood, 1999; 94 (2) :381 -383.
